Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.


French German Italian Portuguese Russian

Treatment Study for Children with Hemophilia B

Clinical Trial Title: 
An open-label, multicenter evaluation of the safety and efficacy of recombinant coagulation Factor IX Fc fusion protein (rFIXFc) in the prevention and treatment of bleeding in previously untreated patients with severe hemophilia B.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Mindy Simpson, MD
Clinical Trial Protocol Description: 
  • Once a week infusions based upon weight and adjusted where needed, including scheduled infusions.
  • Option of on-demand infusion.
  • After 3rd bleed, transition to prophylaxis.
Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have severe hemophilia B.
  • Are 17 years of age or younger.
  • Have never been treated with any product (PUP).

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 942-3034
Contact Name: 
Mindy Simpson, MD